Ingrid V Bassett1, David Wilson, Jessica Taaffe, Kenneth A Freedberg. 1. aDivision of Infectious Diseases bDivision of General Internal Medicine cMedical Practice Evaluation Center, Massachusetts General Hospital dHarvard Center for AIDS Research, Harvard University, Boston, Massachusetts eGlobal AIDS Program, World Bank, Washington, District of Columbia fDepartment of Health Policy and Management, Harvard T.H. Chan School of Public Health, Boston, Massachusetts, USA.
Abstract
PURPOSE OF REVIEW: We reviewed recent literature on conditional and unconditional financial incentives for their impact on improving movement through the HIV care cascade and HIV prevention. RECENT FINDINGS: Concepts from behavioral economics may help improve engagement in HIV care by addressing upstream structural risk factors for HIV, such as poverty, or providing conditional rewards for immediate, measurable outcomes related to HIV care. Incentives have been shown to increase uptake of HIV testing. Yet, few studies to date focus on linkage to care: one large USA-based randomized trial failed to show an effect of incentives; and a smaller trial showed improved linkage to care among drug users, but no difference in virologic suppression. Several small USA-based studies have shown an impact of financial incentives on antiretroviral therapy adherence, but without durability beyond the incentive period. HIV prevention has the most robust evidence for decreasing HIV risk-taking behavior among adolescents and may serve as a model for research on the care cascade. SUMMARY: Financial incentives show promise for improving engagement in HIV testing, care, and prevention. Understanding the durability, scalability, ease of implementation, and cost-effectiveness of these different approaches will be critical for maximizing the impact of incentives in curtailing the HIV epidemic.
PURPOSE OF REVIEW: We reviewed recent literature on conditional and unconditional financial incentives for their impact on improving movement through the HIV care cascade and HIV prevention. RECENT FINDINGS: Concepts from behavioral economics may help improve engagement in HIV care by addressing upstream structural risk factors for HIV, such as poverty, or providing conditional rewards for immediate, measurable outcomes related to HIV care. Incentives have been shown to increase uptake of HIV testing. Yet, few studies to date focus on linkage to care: one large USA-based randomized trial failed to show an effect of incentives; and a smaller trial showed improved linkage to care among drug users, but no difference in virologic suppression. Several small USA-based studies have shown an impact of financial incentives on antiretroviral therapy adherence, but without durability beyond the incentive period. HIV prevention has the most robust evidence for decreasing HIV risk-taking behavior among adolescents and may serve as a model for research on the care cascade. SUMMARY: Financial incentives show promise for improving engagement in HIV testing, care, and prevention. Understanding the durability, scalability, ease of implementation, and cost-effectiveness of these different approaches will be critical for maximizing the impact of incentives in curtailing the HIV epidemic.
Authors: David Tappin; Linda Bauld; David Purves; Kathleen Boyd; Lesley Sinclair; Susan MacAskill; Jennifer McKell; Brenda Friel; Alex McConnachie; Linda de Caestecker; Carol Tannahill; Andrew Radley; Tim Coleman Journal: BMJ Date: 2015-01-27
Authors: James L Sorensen; Nancy A Haug; Kevin L Delucchi; Valerie Gruber; Evan Kletter; Steven L Batki; Jacqueline P Tulsky; Paul Barnett; Sharon Hall Journal: Drug Alcohol Depend Date: 2006-10-23 Impact factor: 4.492
Authors: Bohdan Nosyk; Julio S G Montaner; Guillaume Colley; Viviane D Lima; Keith Chan; Katherine Heath; Benita Yip; Hasina Samji; Mark Gilbert; Rolando Barrios; Réka Gustafson; Robert S Hogg Journal: Lancet Infect Dis Date: 2013-09-27 Impact factor: 25.071
Authors: Damien de Walque; William H Dow; Rose Nathan; Ramadhani Abdul; Faraji Abilahi; Erick Gong; Zachary Isdahl; Julian Jamison; Boniphace Jullu; Suneeta Krishnan; Albert Majura; Edward Miguel; Jeanne Moncada; Sally Mtenga; Mathew Alexander Mwanyangala; Laura Packel; Julius Schachter; Kizito Shirima; Carol A Medlin Journal: BMJ Open Date: 2012-02-08 Impact factor: 3.006
Authors: Maxine L Stitzer; Alexis S Hammond; Tim Matheson; James L Sorensen; Daniel J Feaster; Rui Duan; Lauren Gooden; Carlos Del Rio; Lisa R Metsch Journal: AIDS Patient Care STDS Date: 2018-06-08 Impact factor: 5.078
Authors: Lisa R Metsch; Daniel J Feaster; Lauren Gooden; Tim Matheson; Maxine Stitzer; Moupali Das; Mamta K Jain; Allan E Rodriguez; Wendy S Armstrong; Gregory M Lucas; Ank E Nijhawan; Mari-Lynn Drainoni; Patricia Herrera; Pamela Vergara-Rodriguez; Jeffrey M Jacobson; Michael J Mugavero; Meg Sullivan; Eric S Daar; Deborah K McMahon; David C Ferris; Robert Lindblad; Paul VanVeldhuisen; Neal Oden; Pedro C Castellón; Susan Tross; Louise F Haynes; Antoine Douaihy; James L Sorensen; David S Metzger; Raul N Mandler; Grant N Colfax; Carlos del Rio Journal: JAMA Date: 2016-07-12 Impact factor: 56.272
Authors: Euphemia L Sibanda; Mary Tumushime; Juliet Mufuka; Sue Napierala Mavedzenge; Stephano Gudukeya; Sergio Bautista-Arredondo; Karin Hatzold; Harsha Thirumurthy; Sandra I McCoy; Nancy Padian; Andrew Copas; Frances M Cowan Journal: Lancet Glob Health Date: 2017-09 Impact factor: 26.763
Authors: Antoine D Brantley; Samuel Burgess; Jacquelyn Bickham; Deborah Wendell; DeAnn Gruber Journal: Public Health Rep Date: 2018 Nov/Dec Impact factor: 2.792
Authors: Chinazo O Cunningham; Julia H Arnsten; Chenshu Zhang; Moonseong Heo; Marcus A Bachhuber; John J Jost; Robert Grossberg; Melissa R Stein; Nancy L Sohler Journal: Drug Alcohol Depend Date: 2020-08-11 Impact factor: 4.492
Authors: Shannon Gwin Mitchell; Laura B Monico; Maxine Stitzer; Timothy Matheson; James L Sorensen; Daniel J Feaster; Robert P Schwartz; Lisa Metsch Journal: J Subst Abuse Treat Date: 2018-07-22